Clinical features ofBimdeletion polymorphism and its relation with crizotinib primary resistance in Chinese patients withALK/ROS1fusion-positive non-small cell lung cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Clinical features ofBimdeletion polymorphism and its relation with crizotinib primary resistance in Chinese patients withALK/ROS1fusion-positive non-small cell lung cancer

Published:2017-03-27 Issue:15 Volume:123 Page:2927-2935
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Zhang Limin¹^ORCID,Jiang Tao¹,Li Xuefei²,Wang Yan¹,Zhao Chao²,Zhao Sha¹,Xi Lei¹,Zhang Shijia¹,Liu Xiaozhen¹,Jia Yijun¹,Yang Hui¹,Shi Jinpeng¹,Su Chunxia¹,Ren Shengxiang¹,Zhou Caicun¹

Affiliation:

1. Department of Medical Oncology, Shanghai Pulmonary Hospital and Thoracic Cancer Institute; Tongji University School of Medicine; Shanghai China

2. Department of Lung Cancer and Immunology, Shanghai Pulmonary Hospital; Tongji University School of Medicine; Shanghai China

Funder

National Natural Science Foundation of China

Shanghai Municipal Commission of Health and Family Planning

Outstanding Young Physician Program of the Shanghai Municipal Commission of Health and Family Planning

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference46 articles.

1. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer;Kwak;N Engl J Med.,2010

2. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK;Shaw;J Clin Oncol.,2009

3. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer;Soda;Nature.,2007

4. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis;Shaw;Lancet Oncol.,2011

5. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer;Shaw;N Engl J Med.,2013

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey.;Lung Cancer: Targets and Therapy;2024-06

2. ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies;Cancer Drug Resistance;2024-05-23

3. Translational Research in ROS1-Positive NSCLC: Are We Moving Out of the Six Blind Men and the Elephant Stage?;Journal of Thoracic Oncology;2024-04

4. CD74/SLC34A2-ROS1 Fusion Variants Involving the Transmembrane Region Predict Poor Response to Crizotinib in NSCLC Independent of TP53 Mutations;Journal of Thoracic Oncology;2023-12

5. c-Kit Receptors as a Therapeutic Target in Cancer: Current Insights;OncoTargets and Therapy;2023-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3